ClinicalTrials.gg
CompletedNCT05952856Updated Sep 24, 2026Results posted

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

A Phase 3 interventional study of Enlicitide Decanoate and Placebo in Hypercholesterolemia and Familial Hypercholesterolemia, sponsored by Merck Sharp & Dohme LLC. Completed at 168 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,912
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Hypercholesterolemia by Merck & Co., Inc — 1 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · Merck & Co., Inc.

Enrollment
3rd of 27
2,912 · median 500
Started
2023
with 3 others
Phase 3
17 of 29
1 open now
Registered
22nd of 29
by date

Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 3rd largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 17 in phase 3, and was the 22nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 29 studies in Hypercholesterolemia by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Hypercholesterolemia by Merck & Co., Inc, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.

03

Conditions studied

  • Hypercholesterolemia
  • Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a history of a major atherosclerotic cardiovascular disease (ASCVD) event and LDL-C ≥55 mg/dL OR, if no history of a major ASCVD event, has intermediate to high risk for development of a first major ASCVD event and LDL-C ≥70 mg/dL.
  • Is treated with a moderate- or high-intensity statin OR is treated with low-intensity statin with documentation of intolerance to a moderate or high-intensity statin OR is not receiving statins with documentation of statin intolerance
  • If on any lipid-lowering therapies (LLTs), should be on a stable dose with no planned medication change.

Exclusion criteria

Exclusion Criteria:

  • Has a history of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria, compound heterozygous FH, or double heterozygous FH
  • Has a history of heart failure or heart failure hospitalization within 3 months before first study visit
  • Is undergoing or previously underwent an LDL-C apheresis program within 3 months before first study visit or plans to initiate an LDL-C apheresis program
  • Was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors without adequate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,912 participants (actual)

Study arms

  • Experimental
    Enlicitide Decanoate

    Participants will receive 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks.

    Drug: Enlicitide Decanoate

  • Placebo comparator
    Placebo

    Participants will receive enlicitide decanoate-matching placebo orally QD for up to 52 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24

    Blood samples collected at baseline and Week 24 were used to assess mean percent change in LDL-C.

    Time frame: Baseline and Week 24

  2. Number of Participants With One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 60 weeks

  3. Number of Participants Who Discontinued Study Drug Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Mean Percent Change From Baseline in LDL-C at Week 52

    Blood samples collected at baseline and Week 52 were used to assess mean percent change in LDL-C.

    Time frame: Baseline and Week 52

  2. Mean Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24

    Blood samples collected at baseline and Week 24 were used to assess mean percent change in non-HDL-C.

    Time frame: Baseline and Week 24

  3. Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24

    Blood samples collected at baseline and Week 24 were used to assess mean percent change in ApoB.

    Time frame: Baseline and Week 24

  4. Percent Change From Baseline in Lipoprotein(a) (Lp(a)) at Week 24

    Blood samples collected at baseline and Week 24 were used to assess percent change in Lp(a).

    Time frame: Baseline and Week 24

  5. Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24

    Blood samples collected at baseline and Week 24 were used to assess the percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline. Participants who did not have a Week 24 assessment are considered as not being at the LDL-C goal.

    Time frame: Baseline and Week 24

  6. Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24

    Blood samples collected at baseline and Week 24 were used to assess the percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline. Participants who did not have a Week 24 assessment are considered as not being at the LDL-C goal.

    Time frame: Baseline and Week 24

07

Results

Posted Aug 6, 2026

Participant flow

Participants ≥18 years old with a prior major atherosclerotic cardiovascular disease (ASCVD) event and low-density lipoprotein cholesterol (LDL-C) ≥55 mg/dL (≥1.42 mmol/L) or, if they had no prior ASCVD event, were at intermediate-to-high risk for a first major ASCVD event with LDL-C ≥70 mg/dL (≥1.81 mmol/L) were eligible to be enrolled in this study.

Participant flow — Overall Study
MilestoneEnlicitide DecanoatePlacebo
Started1940969
Treated1935969
Completed1831918
Not completed10951
Withdrew: Legally accepted representative unavailable01
Withdrew: Death158
Withdrew: Lost to follow-up32
Withdrew: Physician decision21
Withdrew: Mistakenly randomized not treated20
Withdrew: Withdrawal by subject8535
Withdrew: Enrolled in another non-enlicitide study01
Withdrew: Refused to continue in study10
Withdrew: Lost interest10
Withdrew: Participant moved03

Outcome measures

PrimaryMean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24

Blood samples collected at baseline and Week 24 were used to assess mean percent change in LDL-C.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24
Percent changeEnlicitide DecanoatePlacebo
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24-57.1 (-61.8 to -52.5)3.0 (0.9 to 5.1)
Statistical analysis
  • Enlicitide Decanoate vs Placebo · ANCOVA · p = <0.001 (1-sided) · Difference in means: -55.8 · 95% CI -60.9 to -50.7Based on the washout and bootstrap imputation method through the ANCOVA model with treatment and the stratification factors (renal function and geographic region) as fixed effects and baseline as a covariate.
Post-hocMean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24 Reanalysis (Post-hoc )

Blood samples collected at baseline and Week 24 were used to assess mean percent change in LDL-C. Data reanalysed according to revised data handling rules treating beta-quantification (BQ) values \</=0 as missing.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24 Reanalysis (Post-hoc )
Percent changeEnlicitide DecanoatePlacebo
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24 Reanalysis (Post-hoc )-59.6 (-61.1 to -58.1)3.0 (0.9 to 5.1)
Statistical analysis
  • Enlicitide Decanoate vs Placebo · ANCOVA · p = <0.001 (1-sided) · Difference in means: -59.7 · 95% CI -62.3 to -57.1Based on the washout and bootstrap imputation method through the ANCOVA model with treatment and the stratification factors (renal function and geographic region) as fixed effects and baseline as a covariate.
PrimaryNumber of Participants With One or More Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 60 weeks
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events (AEs)
ParticipantsEnlicitide DecanoatePlacebo
Number of Participants With One or More Adverse Events (AEs)1244602
Statistical analysis
  • Enlicitide Decanoate vs Placebo · Difference in percentage: 2.2 · 95% CI -1.5 to 5.9Miettinen \& Nurminen method
PrimaryNumber of Participants Who Discontinued Study Drug Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to an AE
ParticipantsEnlicitide DecanoatePlacebo
Number of Participants Who Discontinued Study Drug Due to an AE6040
SecondaryMean Percent Change From Baseline in LDL-C at Week 52

Blood samples collected at baseline and Week 52 were used to assess mean percent change in LDL-C.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in LDL-C at Week 52
Percent changeEnlicitide DecanoatePlacebo
Mean Percent Change From Baseline in LDL-C at Week 52-50.4 (-54.2 to -46.6)4.0 (1.7 to 6.3)
Statistical analysis
  • Enlicitide Decanoate vs Placebo · ANCOVA · p = <0.001 (1-sided) · Difference in means: -47.6 · 95% CI -52.7 to -42.5Based on the washout and bootstrap imputation method through the ANCOVA model with treatment and the stratification factors (renal function and geographic region) as fixed effects and baseline as a covariate.
Post-hocMean Percent Change From Baseline in LDL-C at Week 52 Reanalysis (Post-hoc )

Blood samples collected at baseline and Week 52 were used to assess mean percent change in LDL-C. Data reanalysed according to revised data handling rules treating BQ values \</=0 as missing.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in LDL-C at Week 52 Reanalysis (Post-hoc )
Percent changeEnlicitide DecanoatePlacebo
Mean Percent Change From Baseline in LDL-C at Week 52 Reanalysis (Post-hoc )-52.7 (-54.4 to -50.9)4.0 (1.7 to 6.3)
Statistical analysis
  • Enlicitide Decanoate vs Placebo · ANCOVA · p = <0.001 (1-sided) · Difference in means: -52.4 · 95% CI -55.1 to -49.7Based on the washout and bootstrap imputation method through the ANCOVA model with treatment and the stratification factors (renal function and geographic region) as fixed effects and baseline as a covariate.
SecondaryMean Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24

Blood samples collected at baseline and Week 24 were used to assess mean percent change in non-HDL-C.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24
Percent changeEnlicitide DecanoatePlacebo
Mean Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24-53.7 (-55.0 to -52.5)2.6 (0.8 to 4.5)
Statistical analysis
  • Enlicitide Decanoate vs Placebo · ANCOVA · p = <0.001 (1-sided) · Difference in means: -53.4 · 95% CI -55.5 to -51.2Based on the washout and bootstrap imputation method through the ANCOVA model with treatment and the stratification factors (renal function and geographic region) as fixed effects and baseline as a covariate.
SecondaryMean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24

Blood samples collected at baseline and Week 24 were used to assess mean percent change in ApoB.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24
Percent changeEnlicitide DecanoatePlacebo
Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24-49.6 (-50.8 to -48.5)2.9 (1.3 to 4.4)
Statistical analysis
  • Enlicitide Decanoate vs Placebo · ANCOVA · p = <0.001 (1-sided) · Difference in means: -50.3 · 95% CI -52.1 to -48.5Based on the washout and bootstrap imputation method through the ANCOVA model with treatment and the stratification factors (renal function and geographic region) as fixed effects and baseline as a covariate.
SecondaryPercent Change From Baseline in Lipoprotein(a) (Lp(a)) at Week 24

Blood samples collected at baseline and Week 24 were used to assess percent change in Lp(a).

Time frame:
Baseline and Week 24
Reported as:
Median · Percent change
Percent Change From Baseline in Lipoprotein(a) (Lp(a)) at Week 24
Percent changeEnlicitide DecanoatePlacebo
Percent Change From Baseline in Lipoprotein(a) (Lp(a)) at Week 24-29.0 (-96.1 to 476.0)0.0 (-76.6 to 430.3)
Statistical analysis
  • Enlicitide Decanoate vs Placebo · 1-sided · p = <0.001 (The aligned rank stratified Wilcoxon test with the randomization stratification factors (renal function and geographic region) as strata.) · Median of differences: -28.2 · 95% CI -30.3 to -26.0Based on the Hodges-Lehmann estimation.
SecondaryPercentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24

Blood samples collected at baseline and Week 24 were used to assess the percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline. Participants who did not have a Week 24 assessment are considered as not being at the LDL-C goal.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24
Percentage of participantsEnlicitide DecanoatePlacebo
Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 2470.31.5
Statistical analysis
  • Enlicitide Decanoate vs Placebo · Difference in percentage: 68.8 · 95% CI 66.5 to 70.9
SecondaryPercentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24

Blood samples collected at baseline and Week 24 were used to assess the percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline. Participants who did not have a Week 24 assessment are considered as not being at the LDL-C goal.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24
Percentage of participantsEnlicitide DecanoatePlacebo
Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 2467.51.2
Statistical analysis
  • Enlicitide Decanoate vs Placebo · Difference in percentage: 66.3 · 95% CI 64.1 to 68.5

Adverse events

Collected over All-cause mortality (ACM): From randomization Up to 60 weeks; Adverse Event (AE): From first treatment Up to 60 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enlicitide 20 mg15/1,940 (0.8%)191/1,935 (9.9%)0/1,935 (0%)
Placebo8/969 (0.8%)116/969 (12%)0/969 (0%)
Most frequent serious events
Showing 10 of 230
Most frequent serious events
EventEnlicitide 20 mgPlacebo
PneumoniaInfections and infestations5/19357/969
Angina unstableCardiac disorders9/19356/969
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/19355/969
Chest painGeneral disorders9/19351/969
Atrial fibrillationCardiac disorders2/19354/969
Acute myocardial infarctionCardiac disorders7/19352/969
Cardiac failureCardiac disorders5/19353/969
OsteoarthritisMusculoskeletal and connective tissue disorders2/19353/969
Cerebrovascular accidentNervous system disorders1/19353/969
Transient ischaemic attackNervous system disorders1/19353/969

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Enlicitide DecanoatePlaceboTotal
Mean62.8 ± 10.762.7 ± 10.762.8 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Enlicitide DecanoatePlaceboTotal
Female7753671142
Male11656021767
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enlicitide DecanoatePlaceboTotal
Hispanic or Latino545258803
Not Hispanic or Latino13857062091
Unknown or Not Reported10515
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enlicitide DecanoatePlaceboTotal
American Indian or Alaska Native426
Asian512253765
Native Hawaiian or Other Pacific Islander000
Black or African American17379252
White10305381568
More than one race22197318
Unknown or Not Reported000
Baseline Statin Dose Intensity
Baseline Statin Dose Intensity(Participants)Enlicitide DecanoatePlaceboTotal
No statin therapy6535100
Low intensity241135
Moderate intensity8123841196
High intensity10395391578
Baseline Low-density Lipoprotein Cholesterol (LDL-C)
Baseline Low-density Lipoprotein Cholesterol (LDL-C)(mg/dL)Enlicitide DecanoatePlaceboTotal
Mean95.0 ± 38.898.3 ± 39.296.1 ± 38.9
08

Study locations

168 sites
  • Alliance for Multispecialty Research, LLC ( Site 0093)
    Daphne, Alabama 36526, United States
  • G&L Research ( Site 0043)
    Foley, Alabama 36535, United States
  • Synexus Clinical Research US, Inc.-Synexus Clinical Research US, Inc - Central Phoenix ( Site 0084)
    Phoenix, Arizona 85020, United States
  • National Heart Institute-Research ( Site 0087)
    Beverly Hills, California 90211, United States
  • Clinical Trials Research ( Site 0115)
    Sacramento, California 95821, United States
  • Velocity Clinical Research, Banning ( Site 0017)
    San Bernardino, California 92408, United States
  • Emerson Clinical Research Institute ( Site 0118)
    Washington D.C., District of Columbia 20009, United States
  • Excel Medical Clinical Trials ( Site 0053)
    Boca Raton, Florida 33434, United States
  • Alliance for Multispecialty Research, LLC ( Site 0088)
    Coral Gables, Florida 33134, United States
  • Alliance for Multispecialty Research, LLC ( Site 0094)
    Fort Myers, Florida 33912, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 0018)
    Hallandale, Florida 33009, United States
  • Jacksonville Center for Clinical Research ( Site 0049)
    Jacksonville, Florida 32216, United States
  • South Broward Research ( Site 0051)
    Miramar, Florida 33027, United States
  • Clinical Research Trials of Florida ( Site 0063)
    Tampa, Florida 33607, United States
  • East Coast Institute for Research, LLC ( Site 0033)
    Macon, Georgia 31210, United States
  • Healthcare Research Network - Chicago ( Site 0052)
    Flossmoor, Illinois 60422, United States
  • Synexus Clinical Research US, Inc. ( Site 0109)
    Evansville, Indiana 47714, United States
  • Midwest Institute For Clinical Research ( Site 0059)
    Indianapolis, Indiana 46260, United States
  • Alliance for Multispecialty Research, LLC ( Site 0028)
    Lexington, Kentucky 40509, United States
  • L-MARC Research Center ( Site 0001)
    Louisville, Kentucky 40213, United States
  • Velocity Clinical Research, Covington ( Site 0068)
    Covington, Louisiana 70433, United States
  • Velocity Clinical Research Rockville ( Site 0082)
    Rockville, Maryland 20854, United States
  • Velocity Clinical Research, Gulfport ( Site 0039)
    Gulfport, Mississippi 39503, United States
  • Healthcare Research Network - St. Louis ( Site 0054)
    Hazelwood, Missouri 63042, United States
  • Jubilee Clinical Research ( Site 0106)
    Las Vegas, Nevada 89106, United States
  • AB Clinical Trials ( Site 0070)
    Las Vegas, Nevada 89119, United States
  • New Mexico Clinical Research & Osteoporosis Center ( Site 0005)
    Albuquerque, New Mexico 87106, United States
  • Velocity Clinical Research, Syracuse ( Site 0021)
    East Syracuse, New York 13057, United States
  • Icahn School of Medicine at Mount Sinai-Cardiology ( Site 0002)
    New York, New York 10029, United States
  • Lillestol Research ( Site 0026)
    Fargo, North Dakota 58104, United States
  • altoona center for clinical research ( Site 0089)
    Duncansville, Pennsylvania 16635, United States
  • Cardiology Consultants of Philadelphia Yardley ( Site 0097)
    Yardley, Pennsylvania 19067, United States
  • Piedmont Research Partners ( Site 0090)
    Fort Mill, South Carolina 29707, United States
  • Velocity Clinical Research, Greenville ( Site 0023)
    Greenville, South Carolina 29615, United States
  • Coastal Carolina Research Center ( Site 0006)
    North Charleston, South Carolina 29405, United States
  • Monument Health Clinical Research, a department of Monument -Monument Health Clinical Research, a d ( Site 0009)
    Rapid City, South Dakota 57701, United States
  • Holston Medical Group ( Site 0048)
    Kingsport, Tennessee 37660, United States
  • Alliance for Multispecialty Research, LLC ( Site 0008)
    Knoxville, Tennessee 37920, United States
  • Velocity Clinical Research, Dallas ( Site 0114)
    Dallas, Texas 75230, United States
  • Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0111)
    Houston, Texas 77030, United States
  • Clinical Trials of Texas, LLC ( Site 0103)
    San Antonio, Texas 78229, United States
  • Synexus Clinical Research US, Inc. ( Site 0110)
    Salt Lake City, Utah 84106, United States
  • Velocity Clinical Research, Salt Lake City ( Site 0019)
    West Jordan, Utah 84088, United States
  • Manassas Clinical Research Center ( Site 0007)
    Manassas, Virginia 20110, United States
  • Health Research of Hampton Roads, Inc. ( Site 0044)
    Newport News, Virginia 23606, United States
  • Alliance for Multispecialty Research, LLC ( Site 0101)
    Norfolk, Virginia 23502, United States
  • National Clinical Research, Inc ( Site 0061)
    Richmond, Virginia 23294, United States
  • Centricity Research Suffolk Family Medicine ( Site 0092)
    Suffolk, Virginia 23435, United States
  • Rainier Clinical Research Center ( Site 0116)
    Renton, Washington 98057, United States
  • CEDIC ( Site 0612)
    CABA, Buenos Aires C1060ABN, Argentina
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0605)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
  • Instituto de Investigaciones Clinicas Zarate ( Site 0600)
    Zárate, Buenos Aires B2800DGH, Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0604)
    Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina
  • Fundación Respirar ( Site 0610)
    Buenos Aires, Buenos Aires F.D. C1426ABP, Argentina
  • Centro de Investigaciones Metabólicas (CINME)-Cardiology ( Site 0620)
    CABA, C1056ABI, Argentina
  • Beijing Anzhen Hospital, Capital Medical University-Cardiovascular ( Site 3300)
    Beijing, Beijing Municipality 100029, China
  • Beijing Friendship Hospital Affiliate of Capital University-Cardiology ( Site 3303)
    Beijing, Beijing Municipality 100050, China
  • The Second Affiliated Hospital of Chongqing Medical University ( Site 3320)
    Chongqing, Chongqing Municipality 400072, China
  • Chongqing University Three Gorges Hospital ( Site 3321)
    Chongqing, Chongqing Municipality 404000, China
  • Guangdong Provincial People's Hospital-Cardiology ( Site 3304)
    Guangzhou, Guangdong 510080, China
  • Zhujiang Hospital of Southern Medical University ( Site 3329)
    Guangzhou, Guangdong 510280, China
  • Huizhou Municipal Central Hospital ( Site 3379)
    Huizhou, Guangdong 516001, China
  • The University of Hong Kong-Shenzhen Hospital-Cardiovascular department ( Site 3318)
    Shenzhen, Guangdong 518053, China
  • Jingzhou Central Hospital-Cardiology ( Site 3376)
    Jingzhou, Hubei 434036, China
  • Wuhan Fourth Hospital ( Site 3356)
    Wuhan, Hubei 430030, China
  • Hunan Provincial People's Hospital-Cardiology ( Site 3317)
    Changsha, Hunan 410005, China
  • Changzhou Second People's Hospital-Cardiology ( Site 3373)
    Changzhou, Jiangsu 213000, China
  • Northern Jiangsu People's Hospital ( Site 3308)
    Yangzhou, Jiangsu 225001, China
  • The Third Hospital of Nanchang - Fuhe-cardiology ( Site 3378)
    Nanchang, Jiangxi 330003, China
  • Siping Central People's Hospital-Cardiovascular Department ( Site 3311)
    Siping, Jilin 136000, China
  • Xianyang Hospital of Yan'an University ( Site 3340)
    Xianyang, Shaanxi 712000, China
  • Chengdu Second Municipal People's Hospital ( Site 3332)
    Chengdu, Sichuan 610021, China
  • People's Hospital of Lishui City-department of cardiovascular ( Site 3302)
    Lishui, Zhejiang 323000, China
  • Fundación Centro de Investigación Clínica CIC ( Site 0906)
    Medellín, Antioquia 050021, Colombia
  • Ciensalud Ips S A S ( Site 0903)
    Barranquilla, Atlántico 08001, Colombia
  • Clinica de la Costa S.A.S. ( Site 0902)
    Barranquilla, Atlántico 080020, Colombia
  • Salud SURA Calle 100 ( Site 0918)
    Bogotá, Cundinamarca 110231, Colombia
  • Healthy Medical Center S.A.S ( Site 0913)
    Zipaquirá, Cundinamarca 250252, Colombia
  • Fundación Valle del Lili ( Site 0904)
    Cali, Valle del Cauca Department 760032, Colombia
  • Unterfrintroper Hausarztzentrum Klinische Forschung ( Site 1542)
    Essen, North Rhine-Westphalia 45359, Germany
  • Universitaetsklinikum Carl Gustav Carus Dresden-Universitätsstudienzentrum für Stoffwechselerkranku ( Site 1508)
    Dresden, Saxony 01307, Germany
  • Hausarzt- und Diabetologische Schwerpunktpraxis Hohenmölsen - Weiβenfels ( Site 1527)
    Hohenmölsen, Saxony-Anhalt 06679, Germany
  • Zentralklinik Bad Berka ( Site 1530)
    Bad Berka, Thuringia 99437, Germany
  • Velocity Clinical Research GmbH Berlin ( Site 1502)
    Berlin, 10787, Germany
  • Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1533)
    Berlin, 12203, Germany
  • Hillel Yaffe Medical Center ( Site 1705)
    Hadera, 3810101, Israel
  • Rambam Health Care Campus-internal department ( Site 1718)
    Haifa, 3109601, Israel
  • Shaare Zedek Medical Center ( Site 1710)
    Jerusalem, 9103102, Israel
  • Hadassah Medical Center ( Site 1706)
    Jerusalem, 9112001, Israel
  • Hadassah Medical Center ( Site 1709)
    Jerusalem, 9112001, Israel
  • Meir Medical Center. ( Site 1714)
    Kfar Saba, 4428164, Israel
  • Rabin Medical Center ( Site 1720)
    Petah Tikva, 4941 492, Israel
  • Sheba Medical Center ( Site 1708)
    Ramat Gan, 5265601, Israel
  • Yitzhak Shamir Medical Center. ( Site 1712)
    Ẕerifin, 7033001, Israel
  • Fondazione Policlinico Tor Vergata ( Site 1809)
    Rome, Lazio 00133, Italy
  • Centro Cardiologico Monzino ( Site 1804)
    Milan, Milano 20138, Italy
  • ASST Grande Ospedale Metropolitano Niguarda-Unità Ricerche Cliniche della Cardiologia 4 ( Site 1811)
    Milan, Milano 20162, Italy
  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino ( Site 1801)
    Turin, Piedmont 10126, Italy
  • Azienda Ospedaliera Sant'Andrea-Department of Clinical and Molecular Medicine ( Site 1807)
    Rome, Roma 00189, Italy
  • Azienda Ospedaliera Garibaldi ( Site 1810)
    Catania, 95122, Italy

Showing the first 100 of 168 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, Kourpanidis S, Lepor NE, Tsukamoto K, Mendizabal G, Nunez J, Zhang W, Zhu P, Zhuo M, Ballantyne CM; CORALreef Lipids Investigators. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026 Feb 5;394(6):529-539. doi: 10.1056/NEJMoa2511002. PubMed 41879224 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jul 2025, 23 months.

Results were first posted in Aug 2026, 1 year after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2023
First posted
Jul 19, 2023
StartActual
Aug 10, 2023
Primary completionActual
Jul 28, 2025
CompletionActual
Jul 28, 2025
Results first posted
Aug 6, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05952856
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Aug 10, 2023
Primary completion
Jul 28, 2025
Completion
Jul 28, 2025
Results posted
Aug 6, 2026
Last update
Sep 24, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-0616

Start the discussion